levetiracetam pharmaswiss 1000 mg õhukese polümeerikattega tablett
pharmaswiss ceska republika s.r.o. - levetiratsetaam - õhukese polümeerikattega tablett - 1000mg 200tk; 1000mg 10tk; 1000mg 20tk; 1000mg 60tk
olanzapine polpharma suus dispergeeruv tablett
pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 10mg 30tk; 10mg 56tk
olanzapine polpharma suus dispergeeruv tablett
pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 15mg 56tk; 15mg 28tk; 15mg 30tk
olanzapine polpharma suus dispergeeruv tablett
pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 20mg 30tk; 20mg 56tk; 20mg 28tk
bortezomib pharmaswiss süstelahuse pulber
pharmaswiss ceska republika s.r.o. - bortesomiib - süstelahuse pulber - 3,5mg 10ml 1tk
quetiapine polpharma õhukese polümeerikattega tablett
pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 100mg 90tk
protopic
leo pharma a/s - takroliimus - dermatiit, atoopiline - muud dermatoloogilised preparaadid - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. esinevad neli või enam korda aastas), kes on olnud esialgse vastuse maksimaalselt kuue nädala jooksul ravi kaks korda päevas takroliimus salvi (kahjustused eemaldatud, peaaegu kustutatud või kergelt kahjustatud).
kyntheum
leo pharma a/s - brodalumab - psoriaas - immunosupressandid - kyntheum on näidustatud mõõduka kuni raske naastulise psoriaasi raviks täiskasvanud patsientidel, kes saavad süsteemset ravi.
adtralza
leo pharma a/s - tralokinumab - dermatiit, atoopiline - muud dermatoloogilised preparaadid - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.
ribavirin teva pharma b.v.
teva b.v. - ribavirin - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 ja 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 ja 5.